Biotech Stocks — Analysis & Key Financial Data
Biotech Stocks focus on companies that operate in a specific niche or sub‑industry, where business models, risk drivers, and valuation frameworks tend to rhyme more closely with each other than with the broader market. Grouping stocks by theme makes it easier to understand how fundamentals and pricing compare inside the same opportunity set. On this page you can review biotech stocks with Investment Scores, base valuations, and key financial metrics on Invest Viable. The tag is a transparent grouping tool — a way to organise research around a theme — rather than a recommendation list, so you can still apply your own judgement and valuation work.
- Stocks matching
- 3,190
- Latest data
- 2026-06-28
Highest Investment Scores in Biotech Stocks
Top-rated stocks by Investment Score
- Price
- $91.19
- Fair Value
- $355.29
- Market Cap
- $21.2B
- Margin
- +289.6%
- Price
- $175.25
- Fair Value
- $263.72
- Market Cap
- $2.3B
- Margin
- +50.5%
- Price
- $41.36
- Fair Value
- $55.84
- Market Cap
- $1.1B
- Margin
- +35.0%
- Price
- $72.34
- Fair Value
- $69.18
- Market Cap
- $5.1B
- Margin
- -4.4%
Biotech Stock List
| Company | Price | Fair Value | Score | Market Cap | P/E | EPS | Yield |
|---|---|---|---|---|---|---|---|
Leishen Energy Holding Co., Ltd. LSE | $4.37 | — | 39 | $71M | 58.4 | $0.07 | 0.00% |
OptimumBank Holdings, Inc. OPHC | $5.84 | $27.68 | 77 | $71M | 3.9 | $1.46 | 0.00% |
XBiotech Inc. XBIT | $2.30 | — | 32 | $71M | -1.8 | $-1.32 | 0.00% |
Vivani Medical, Inc. VANI | $1.24 | — | 19 | $71M | -3.0 | $-0.33 | 0.00% |
Pliant Therapeutics, Inc. PLRX | $1.14 | — | 23 | $71M | -0.6 | $-1.83 | 0.00% |
Outlook Therapeutics, Inc. OTLK | $1.59 | — | 23 | $70M | -1.3 | $-0.74 | 0.00% |
Odysight.ai Inc. ODYS | $4.16 | — | 26 | $70M | -3.8 | $-1.10 | 0.00% |
BranchOut Food Inc. BOF | $4.60 | — | 19 | $70M | -6.8 | $-0.65 | 0.00% |
AudioEye, Inc. AEYE | $5.81 | — | 32 | $70M | -18.7 | $-0.30 | 0.00% |
Siebert Financial Corp. SIEB | $1.65 | $4.39 | 58 | $70M | -12.2 | $-0.14 | 0.00% |
BeyondSpring Inc. BYSI | $1.75 | — | 23 | $69M | -8.9 | $-0.19 | 0.00% |
Pearl Diver Credit Company Inc. PDCC | $9.96 | — | 52 | $69M | 4.0 | $2.68 | 25.00% |
Pearl Diver Credit Company Inc. PDPA | $25.15 | — | 52 | $69M | 4.0 | $2.68 | 25.00% |
Safe Pro Group Inc. Common Stock SPAI | $4.33 | — | 16 | $69M | -5.4 | $-0.64 | 0.00% |
Catalyst Bancorp, Inc. CLST | $16.51 | $4.48 | 61 | $69M | 30.4 | $0.58 | 0.00% |
Drilling Tools International Corp. DTI | $1.93 | — | 48 | $69M | -19.9 | $-0.10 | 0.00% |
Sera Prognostics, Inc. SERA | $1.82 | — | 26 | $69M | -2.8 | $-0.64 | 0.00% |
Seres Therapeutics, Inc. MCRB | $7.89 | — | 32 | $69M | -1.4 | $-4.89 | 0.00% |
GrabAGun Digital Holdings Inc. PEW | $2.28 | — | 26 | $68M | -12.3 | $-0.17 | 0.00% |
LENSAR Inc LNSR | $5.71 | — | 42 | $68M | 5.7 | $2.42 | 0.00% |
Regis Corporation RGS | $28.00 | $27.68 | 45 | $68M | 0.6 | $44.32 | 0.00% |
GEN Restaurant Group, Inc. GENK | $1.97 | $43.47 | 26 | $67M | -2.8 | $-0.73 | 1.47% |
Nakamoto Inc. NAKA | $3.95 | — | 10 | $67M | -0.1 | $-18.22 | 0.00% |
AmeriServ Financial, Inc. ASRV | $3.88 | $7.45 | 68 | $66M | 11.8 | $0.32 | 3.08% |
Brilliant Earth Group, Inc. BRLT | $1.13 | $0.81 | 42 | $66M | -3.4 | $-0.30 | 0.00% |
About biotech stocks
Biotech is the part of healthcare where standard valuation conventions get strained the most. A pre-revenue clinical-stage biotech has no current cash flow to discount and can have a market capitalisation that's a multiple of its tangible book value because the entire investment thesis sits in pipeline optionality and probability of approval. Commercial-stage biotechs with one or two marketed products are closer to specialty pharma but still carry concentrated single-product or single-therapeutic-area risk that diversified pharma doesn't.
The screener applies the same Investment Score model and base-valuation pipeline to every name on this page, but the outputs are more useful for some types of biotech than others. For commercial-stage names with revenue and earnings, the standard outputs work the way they do anywhere else. For pre-revenue clinical-stage names, the Score is often null and the margins of safety can read as very negative because default DCF inputs produce conservative base values. The page surfaces "—" rather than estimating, and the FAQ flags these cases explicitly.
What this page is for
This page is a screener and reference surface, not editorial coverage. The list above refreshes with each data update; the methodology, FAQ, and related categories below stay in place so the page is useful both for somebody arriving from a specific search and for somebody scanning the industry for the first time.
If you want to value a single biotech stock end-to-end rather than scan the industry, the Invest Viable Valuator walks through the same models we use to compute the base valuations on this page.
Where you'll find Biotech Stocks
This theme typically shows up across the sectors below. Each sector page lists every covered name with the same Investment Score model and base-valuation pipeline.
How we screen Biotech Stocks
A company appears on this page when its primary industry classification is Biotechnology. The screen captures clinical-stage and commercial-stage biotechs across every therapeutic area.
- Listed on a US exchange (NYSE / Nasdaq) and classified as Biotechnology in our industry taxonomy. ADRs of foreign-domiciled biotechs appear when their primary US listing is active.
- Includes pre-revenue clinical-stage names (most of the universe) and commercial-stage biotechs with marketed products. Diagnostics and tools companies are typically classified separately.
- Investment Score and base valuation computed by the same models used elsewhere on Invest Viable. For pre-revenue biotechs, the Score and margins of safety can be null where default-model inputs aren't applicable; the page shows "—" rather than estimating.
Frequently asked questions
What's the difference between Biotech and Pharma on Invest Viable?
Pharma is dominated by large commercial-stage drugmakers with established revenue, marketed portfolios, and patent-cliff calendars. Biotech is heavier on clinical-stage and recently-commercialised names where revenue is small or zero and value depends on pipeline outcomes. Both pages cover companies that develop therapeutics, but the financial profiles inside each are very different.
Why do many biotech stocks show null Investment Scores?
The Investment Score is computed from financial-history inputs — revenue, margins, balance sheet, cash-flow trajectory. Pre-revenue clinical-stage biotechs lack several of those inputs, so the model returns null rather than a partial score. The page surfaces "—" rather than estimating in those cases.
How are clinical-stage biotechs valued?
Practitioners use probability-weighted DCFs that adjust pipeline cash flows by trial-success probability and approval timelines. Our default base valuations apply standard DCF and multiples where the data supports it; for genuinely pre-revenue names, traditional valuation outputs can be very wide and the screener shows them with that caveat in the FAQ and methodology pages.
Why do biotech stocks sometimes show very large negative margins of safety?
A negative margin means market price is above the base valuation our default models compute. For early-stage biotech, default DCF assumptions produce conservative base values that markets routinely trade above when investors price in pipeline optionality. The number flags the gap rather than passing judgement on it.
Does Invest Viable recommend specific biotech stocks?
No. This page is a screener and analysis surface, not a recommendation list. Each stock is shown with its underlying financial data, base valuation, and Investment Score so you can do your own research. Invest Viable does not publish buy or sell calls on individual securities.